posted
DNAPrint Genomics, Inc. Appoints Dr. Barbara Handelin as Director of Diagnostics Market Wire
SARASOTA, FL -- (MARKET WIRE) -- 01/10/06 -- DNAPrint(TM) Genomics, Inc. (OTC BB: DNAG), announced today that it has appointed Barbara Handelin, Ph.D., as Director of Diagnostics, in the newly organized subsidiary, DNAPrint Pharmaceuticals, Inc. As Director, Dr. Handelin will be responsible for the commercialization of the Company's pharmacogenomics and personalized medicine products. Dr. Handelin is a seasoned biotech business executive and board certified Medical Geneticist (Molecular and Biochemical Genetics) with more than 18 years of experience in the application of genetics to clinical medicine and drug development research.
Dr. Handelin was Director of the DNA Diagnostics Laboratory at Integrated Genetics (now Genzyme Genetics) starting in 1987 where she helped establish what became the largest commercial DNA testing laboratory in the world. Under her direction, the DNA Diagnostics laboratory was a technological and clinical practice leader in genetic diagnostics, setting the standard for low cost, high fidelity analysis of many mutations in genetically complex diseases and the first laboratory to offer commercial carrier and prenatal gene testing for Huntington's Disease (1987), Cystic Fibrosis (1990), Spinal Muscular Atrophy (1992), Tay Sachs Disease (1993 large scale carrier screening) and Fragile X (1994).
Since 1995, Dr. Handelin has provided business and technical consulting guidance for industry leaders in genetic diagnostics, pharmacogenetics, and drug development. Dr. Handelin has also served on a variety of federal committees and advisory panels on genetic testing and pharmacogenetics, including the Health and Human Services Secretary's Advisory Panel on Genetics, Health and Society and was the Principal Investigator on a DOE ELSI grant on the "The Responsibility of Oversight in Genetics Research: How to Enable Effective Human Subjects Review of Public and Privately Funded Research Programs." Dr. Handelin earned her Ph.D. at the Oregon Health Sciences University and the Massachusetts Institute of Technology.
"Dr. Handelin brings to DNAPrint extensive research and development expertise in the field of Diagnostics, which is crucial to DNAPrint Pharmaceuticals' future growth and development. We are very pleased to be working with her on the development of our diagnostic projects," said Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint Genomics, Inc. and the newly formed DNAPrint Pharmaceuticals, Inc.
"DNAPrint Pharmaceuticals is particularly fortunate to have Dr. Handelin lead our diagnostics division. She possesses the technical expertise and business savvy to develop and bring to market products which address significant market opportunities in an efficient and well executed manner," commented Richard Gabriel, President and CEO of DNAPrint.
-------------------- Veni Vidi Vici Posts: 529 | From: CA | Registered: Jan 2005
| IP: Logged |
posted
The following is a partial article in the Jan issue of "Scientific America". The article does not mention DNAG. It is, in my my opinion, a good read on the possibilities of the near future. Then on the other hand, if you have trouble sleeping at night, this might also help
BIOTECHNOLOGY
Genomes for All Next-generation technologies that make reading DNA fast, cheap and widely accessible are coming in less than a decade. Their potential to revolutionize research and bring about the era of truly personalized medicine means the time to start preparing is now By George M. Church
When the World Wide Web launched in 1993, it seemed to catch on and spread overnight, unlike most new technologies, which typically take at least a decade to move from first "proof of concept" to broad acceptance. But the Web did not really emerge in a single year. It built on infrastructure, including the construction of the Internet between 1965 and 1993, as well as a sudden recognition that resources, such as personal computers, had passed a critical threshold. Vision and market forces also push the development and spread of new technologies. The space program, for example, started with a government vision, and only much later did military and civilian uses for satellites propel the industry to commercial viability. Looking forward to the next technological revolution, which may be in biotechnology, one can begin to imagine what markets, visions, discoveries and inventions may shape its outcome and what critical thresholds in infrastructure and resources will make it possible.......continued at Scientific American Digital
-------------------- Veni Vidi Vici Posts: 529 | From: CA | Registered: Jan 2005
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Smile]](smile.gif)
